Carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus

Lancet Oncol. 2024 Nov 28:S1470-2045(24)00685-5. doi: 10.1016/S1470-2045(24)00685-5. Online ahead of print.

Authors

Vincent J Cogliano¹, Emanuela Corsini¹, Agnès Fournier¹, Heather H Nelson¹, Consolato M Sergi¹, Alexandra M M Antunes¹, Elizabeth K Cahoon¹, Guosheng Chen¹, Talita Duarte-Salles¹, Eric Engels¹, Jingqi Fu¹, Dori Germolec¹, Reza Ghiasvand¹, Blánaid Hicks¹, Bertrand J Jean-Claude¹, Gopabandhu Jena¹, Catharina M Lerche¹, Xilin Li¹, Angela Lupattelli¹, Thomas P Ong¹, Libia Vega¹, Diana R Withrow¹, Alistair B A Boxall¹, Lamia Benbrahim-Tallaa¹, Aline de Conti¹, Andrew Kunzmann¹, Elisa Pasqual¹, Roland Wedekind¹, Xiaobei Deng¹, Yahya Mahamat-Saleh¹, Azam Majidi¹, Laia Peruchet-Noray¹, Julia Rezende Da Silva¹, Eero Suonio¹, Susana Viegas¹, Yue Zhai¹, Heidi Mattock¹, Caterina Facchin¹, Mary K Schubauer-Berigan², Federica Madia²

Affiliations

¹ International Agency for Research on Cancer, Lyon, France.
² International Agency for Research on Cancer, Lyon, France; International Agency for Research on Cancer, Lyon, France.

PMID: 39622256
DOI: 10.1016/S1470-2045(24)00685-5

No abstract available